Targeted Genetics news from FierceBioResearcher
NewsGene therapy helps improve sight of the blind
Two new human trials of a gene therapy for inherited blindness have demonstrated that injecting replacement genes under the retinas of the blind can spur at least partial sight in some volunteers. In Read more...
Biotech co. defends gene therapy trial standards
The death of Jolee Mohr in a gene therapy trial undertaken by Seattle-based Targeted Read more...
| Press ReleasesPRESS RELEASE: Targeted Genetics Announces That FDA Has Removed Hold on Phase I/II Clinical Trial of tgAAC94 Targeted Genetics Announces That FDA Has Removed Hold on Phase I/II Clinical Trial of tgAAC94 for Inflammatory Arthritis Phase II Clinical Trial Protocol Design Underway SEATTLE, WA, Nov 26, Read more... |
Get more Targeted Genetics coverage at:
Paid Research Reports
- Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
- Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
- Biotech 2008 – life sciences industry report (online & print)
- Is there a market for alcoholism pharmacotherapies?
- New report provides Rheumatoid Arthritis market insight